Best Semaglutide For Weight Loss 2026: Is MEDVi the Best GLP-1 Supplier for a Sustainable Online Weight Loss Program?
New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Intro As…
Psyence BioMed Announces Approval for Use of PsyLabs Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
Peptinovo Biopharma in Collaboration with Chemelectiva Announces Breakthrough Manufacturing Innovation for Targeted Chemotherapy
First-of-its-kind semi-synthetic vitamin E product enables scalable, FDA-compliant production of Peptinovo’s proprietary…
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:Â TLSA)…
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced…
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15,…
Miltenyi Biotec Receives ‘Special Recognition Award’ for Pioneering Work in Cell & Gene Therapy at BioSpectrum India Excellence Awards 2025
NEW DELHI, Dec. 9, 2025 /PRNewswire/ -- Miltenyi Biotec has been honoured…
ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc.…